论文部分内容阅读
目的探究血脂康联合辛伐他汀对肥胖型2型糖尿病合并高脂血症患者血脂及血清超敏C-反应蛋白(hs-CRP)的影响。方法选取2013年3月—2014年6月因肥胖型2型糖尿病合并高脂血症入院治疗的94例患者进行研究,随机将其分为研究组和对照组,每组各47例。研究组采用血脂康联合辛伐他汀治疗,对照组采用血脂康治疗。对比治疗前后患者空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、hs-CRP、空腹胰岛素水平、胰岛素抵抗指数等指标变化情况。结果 1研究组治疗后FBG、2 h PG和Hb A1c均低于对照组,差异有统计学意义(P<0.05)。2治疗后研究组空腹胰岛素水平较对照组提高,胰岛素抵抗指数(HOMA-IR)较对照组降低,差异有统计学意义(P<0.05);而两组的体重指数(BMI)差异无统计学意义(P>0.05);3治疗后,两组的LDL-C、TG、TC明显下降,HDL-C明显上升(P<0.05),但研究组的TG明显低于对照组的,差异有统计学意义(P<0.05)。4治疗后,研究组的hs-CRP明显下降,且研究组的hs-CRP明显低于对照组的,差异有统计学意义(P<0.05)。5在治疗过程中,对照组不良反应发生率为4.26%,研究组为2.13%,两组不良反应发生率差异无统计学意义(P>0.05)。结论血脂康联合辛伐他汀治疗肥胖型2型糖尿病合并高脂血症患者的效果较好,能有效地调节血糖和血脂水平,降低hs-CRP,且不良反应少。
Objective To investigate the effects of Xuezhikang combined with simvastatin on serum lipids and serum hs-CRP levels in obese type 2 diabetic patients with hyperlipidemia. Methods From March 2013 to June 2014, 94 patients admitted to hospital for obese type 2 diabetes mellitus with hyperlipidemia were randomly divided into study group and control group, with 47 cases in each group. The study group was treated with Xuezhikang combined with simvastatin, while the control group was treated with Xuezhikang. The levels of fasting blood glucose (FBG), 2 h PG, Hb A1c, TC, TG, HDL-C ), Low density lipoprotein cholesterol (LDL-C), hs-CRP, fasting insulin, insulin resistance index and other indicators. Results 1 After treatment, the FBG, 2 h PG and Hb A1c in the study group were lower than those in the control group, the difference was statistically significant (P <0.05). After treatment, the fasting insulin level in the study group was higher than that in the control group, while the HOMA-IR decreased compared with the control group (P <0.05). There was no significant difference in body mass index (BMI) between the two groups (P> 0.05) .3 After treatment, the levels of LDL-C, TG and TC in the two groups decreased significantly and HDL-C increased significantly (P <0.05), but TG in the study group was significantly lower than that in the control group Significance (P <0.05). After treatment, the hs-CRP in the study group decreased significantly, and the hs-CRP in the study group was significantly lower than that in the control group (P <0.05). 5 In the course of treatment, the incidence of adverse reactions in the control group was 4.26%, and in the study group was 2.13%. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Xuezhikang combined with simvastatin treatment of obese type 2 diabetes patients with hyperlipidemia effect is better, can effectively regulate blood glucose and blood lipid levels, reduce hs-CRP, and less adverse reactions.